218 related articles for article (PubMed ID: 36611492)
1. Donanemab for Alzheimer's Disease: A Systematic Review of Clinical Trials.
Rashad A; Rasool A; Shaheryar M; Sarfraz A; Sarfraz Z; Robles-Velasco K; Cherrez-Ojeda I
Healthcare (Basel); 2022 Dec; 11(1):. PubMed ID: 36611492
[TBL] [Abstract][Full Text] [Related]
2. Evidences and therapeutic advantages of donanemab in the treatment of early Alzheimer's disease.
Shukla AK; Misra S
J Basic Clin Physiol Pharmacol; 2024 Jan; 35(1-2):25-29. PubMed ID: 38053285
[TBL] [Abstract][Full Text] [Related]
3. Donanemab in Early Alzheimer's Disease.
Mintun MA; Lo AC; Duggan Evans C; Wessels AM; Ardayfio PA; Andersen SW; Shcherbinin S; Sparks J; Sims JR; Brys M; Apostolova LG; Salloway SP; Skovronsky DM
N Engl J Med; 2021 May; 384(18):1691-1704. PubMed ID: 33720637
[TBL] [Abstract][Full Text] [Related]
4. Donanemab in Japanese Patients with Early Alzheimer's Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial.
Sato S; Hatakeyama N; Fujikoshi S; Katayama S; Katagiri H; Sims JR
Neurol Ther; 2024 Jun; 13(3):677-695. PubMed ID: 38581616
[TBL] [Abstract][Full Text] [Related]
5. Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging.
Lowe SL; Duggan Evans C; Shcherbinin S; Cheng YJ; Willis BA; Gueorguieva I; Lo AC; Fleisher AS; Dage JL; Ardayfio P; Aguiar G; Ishibai M; Takaichi G; Chua L; Mullins G; Sims JR
J Prev Alzheimers Dis; 2021; 8(4):414-424. PubMed ID: 34585215
[TBL] [Abstract][Full Text] [Related]
6. Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease.
Gueorguieva I; Willis BA; Chua L; Chow K; Ernest CS; Shcherbinin S; Ardayfio P; Mullins GR; Sims JR
Clin Pharmacol Ther; 2023 Jun; 113(6):1258-1267. PubMed ID: 36805552
[TBL] [Abstract][Full Text] [Related]
7. Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
Shcherbinin S; Evans CD; Lu M; Andersen SW; Pontecorvo MJ; Willis BA; Gueorguieva I; Hauck PM; Brooks DA; Mintun MA; Sims JR
JAMA Neurol; 2022 Oct; 79(10):1015-1024. PubMed ID: 36094645
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer's.
Song T; Wang Y; Silverglate BD; Grossberg GT
Expert Opin Drug Metab Toxicol; 2024 Jun; 20(6):411-417. PubMed ID: 38758223
[TBL] [Abstract][Full Text] [Related]
9. Still grasping at straws: donanemab in Alzheimer's disease.
Doggrell SA
Expert Opin Investig Drugs; 2021 Aug; 30(8):797-801. PubMed ID: 34162295
[TBL] [Abstract][Full Text] [Related]
10. Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease.
Wang D; Kowalewski EK; Koch G
Ther Innov Regul Sci; 2022 May; 56(3):501-516. PubMed ID: 35320578
[TBL] [Abstract][Full Text] [Related]
11. How donanemab data address the coverage with evidence development questions.
Klein EG; Schroeder K; Wessels AM; Phipps A; Japha M; Schilling T; Zimmer JA
Alzheimers Dement; 2024 Apr; 20(4):3127-3140. PubMed ID: 38323738
[TBL] [Abstract][Full Text] [Related]
12. Donanemab: Not two without a third.
Kurkinen M
Adv Clin Exp Med; 2023 Oct; 32(10):1085-1087. PubMed ID: 37831471
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis.
Terao I; Kodama W
Ageing Res Rev; 2024 Feb; 94():102203. PubMed ID: 38253184
[TBL] [Abstract][Full Text] [Related]
14. Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease.
Gueorguieva I; Willis BA; Chua L; Chow K; Ernest CS; Wang J; Shcherbinin S; Sims JR; Chigutsa E
Alzheimers Dement (N Y); 2023; 9(2):e12404. PubMed ID: 37388759
[TBL] [Abstract][Full Text] [Related]
15. Souvenaid for Alzheimer's disease.
Burckhardt M; Watzke S; Wienke A; Langer G; Fink A
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD011679. PubMed ID: 33320335
[TBL] [Abstract][Full Text] [Related]
16. Comparative Efficacy, Tolerability, and Acceptability of Donanemab, Lecanemab, Aducanumab, Melatonin, and Aerobic Exercise for a Short Time on Cognitive Function in Mild Cognitive Impairment and Mild Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.
Terao I; Kodama W
J Alzheimers Dis; 2024; 98(3):825-835. PubMed ID: 38461503
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer's Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion.
Esquer A; Blanc F; Collongues N
Neurol Ther; 2023 Dec; 12(6):1883-1907. PubMed ID: 37812325
[TBL] [Abstract][Full Text] [Related]
18. Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies.
Imbimbo BP; Ippati S; Watling M; Imbimbo C
Pharmacol Res; 2023 Jan; 187():106631. PubMed ID: 36586644
[TBL] [Abstract][Full Text] [Related]
19. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.
Villain N; Planche V; Levy R
Rev Neurol (Paris); 2022 Dec; 178(10):1011-1030. PubMed ID: 36184326
[TBL] [Abstract][Full Text] [Related]
20. Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit.
Høilund-Carlsen PF; Alavi A; Barrio JR; Castellani RJ; Costa T; Herrup K; Kepp KP; Neve RL; Perry G; Revheim ME; Robakis NK; Sensi SL; Vissel B
Ageing Res Rev; 2024 Jun; ():102348. PubMed ID: 38830549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
